Featured Research

from universities, journals, and other organizations

New targeted lung cancer drug produces 'dramatic' symptom improvement; Early-stage trial shows promise against tumors driven by ALK gene alteration

Date:
October 28, 2010
Source:
Massachusetts General Hospital
Summary:
A clinical trial of a new targeted drug has provided powerful evidence that it can halt or reverse the growth of lung tumors characterized by a specific genetic abnormality. The multi-institutional research team reports that daily doses of crizotinib shrank the tumors of more than half of a group patients whose tumors were driven by alterations in the anaplastic lymphoma kinase gene and suppressed tumor growth in another one-third of study participants.

A clinical trial of a potential new targeted treatment drug has provided powerful evidence that it can halt or reverse the growth of lung tumors characterized by a specific genetic abnormality.

In their report in the Oct. 28 New England Journal of Medicine, a multi-institutional research team reports that daily doses of the investigational drug crizotinib shrank the tumors of more than half of a group patients whose tumors were driven by alterations in the anaplastic lymphoma kinase (ALK) gene. In another one-third of study participants, crizotinib treatment suppressed tumor growth. Preliminary results of this study were reported at the June 2010 meeting of the American Society for Clinical Oncology.

"Traditionally phase 1 trials have been used to determine the safety of drugs that have never been given to people before," explains Eunice Kwak, MD, PhD, of the Massachusetts General Hospital (MGH) Cancer Center, corresponding author of the study. "In this trial we were always looking for patients whose tumors might be more likely to respond to this drug, since we knew it inhibited the cancer-related proteins ALK and MET. Fortunately, once the first stage of the trial had established the maximum tolerated dose, we had the flexibility to enroll additional patients whose tumors had these molecular abnormalities."

In recent years, cancer researchers have found that genetic abnormalities which spur uncontrolled cellular proliferation underlie several types of cancer. About 12 percent of the cases of non-small-cell lung cancer (NSCLC), the leading cause of cancer death in the U.S., are driven by mutations in a protein called EGFR, and several drugs that target the molecular pathway controlled by EGFR have halted or reversed tumor growth, at least temporarily. In 2007 it was discovered that a rearrangement involving the ALK gene, already associated with several other types of cancer, was behind 2 to 7 percent of NSCLC cases.

Laboratory studies at the MGH and other centers had shown that crizotinib could inhibit activity of both ALK and the MET oncogene, so the current study was designed in two parts. In the first stage patients with any solid tumor that had not responded to standard therapies received increasing daily oral doses of crizotinib to establish the highest dose that would not cause intolerable side effects. Two of the participants in that stage of the trial had ALK-altered NSCLC, and both of them showed what the investigators characterized as 'dramatic' symptom improvement. Based on those results, the second stage was expanded from three to a total of seven sites to enroll additional NSCLC patients with ALK-rearranged tumors.

Of 82 patients with ALK-altered tumors who eventually enrolled in the trial, crizotinib treatment reduced tumor size in at least 47 and halted tumor growth in 27. Among those participants, 63 have continued receiving the drug, some for more than two years. "This therapy is allowing patients to function without pain or a constant cough," Kwak explains. "The most rewarding thing about treating patients with this drug is watching them change from being completely controlled by their cancer to resuming a very normal life."

While results of the current study are promising, additional trials are required to confirm the effectiveness of crizotinib for NSCLC. A phase 3 clinical trial has started enrolling patients, and more information on that trial is available by calling the MGH Cancer Center at 877 789-6100. Kwak, an instructor in Medicine at Harvard Medical School, notes that the fact that the phase 3 trial started only three years after the phase 1 trial began -- a process that took a decade for the first EGFR inhibitor -- reflects the power of prospective tumor genotyping.

"The MGH already had the infrastructure in place to screen tumors for molecular abnormalities, so we were poised to test for ALK rearrangement," she explains. "We were actually able to identify the first patient with such a lung cancer and enroll him in the initial stage of this study four months after the original report of ALK-altered NSCLC was published. Then it was amazing to see his symptoms improve within a matter of weeks. These results are just one more compelling example of what we can do for our patients if we just learn more about their tumors."

The study was supported by Pfizer, which is developing crizotinib for clinical application, and by grants from the Aid for Cancer Research Foundation, the National Cancer Institute, the American Society for Clinical Oncology and other funders. Co-authors of the NEJM report include Alice Shaw, MD, PhD, Jeffrey Clark, MD, and John Iafrate, MD, PhD, MGH Cancer Center; Yung-Jue Bang, MD, PhD, Seoul National University College of Medicine, Korea; D. Ross Camidge, MD, PhD, University of Colorado Cancer Center; Benjamin Solomon, MB, BS, PhD, MacCallum Cancer Centre, Melbourne, Australia; Ravi Salgia, MD, PhD, University of Chicago; Robert Maki, MD, PhD, Memorial Sloan-Kettering Cancer Center; Sai-Hong Ou, MD, PhD, University of California, Irvine; Keith Wilner, PhD, Pfizer Pharmaceuticals; and Geoffrey Shapiro, MD, PhD, Dana-Farber Cancer Institute. Additional co-authors are based at the institutions named above and at Beth Israel Deaconess Medical Center.


Story Source:

The above story is based on materials provided by Massachusetts General Hospital. Note: Materials may be edited for content and length.


Journal References:

  1. Eunice L. Kwak, Yung-Jue Bang, D. Ross Camidge, Alice T. Shaw, Benjamin Solomon, Robert G. Maki, Sai-Hong I. Ou, Bruce J. Dezube, Pasi A. Jδnne, Daniel B. Costa, Marileila Varella-Garcia, Woo-Ho Kim, Thomas J. Lynch, Panos Fidias, Hannah Stubbs, Jeffrey A. Engelman, Lecia V. Sequist, WeiWei Tan, Leena Gandhi, Mari Mino-Kenudson, Greg C. Wei, S. Martin Shreeve, Mark J. Ratain, Jeffrey Settleman, James G. Christensen, Daniel A. Haber, Keith Wilner, Ravi Salgia, Geoffrey I. Shapiro, Jeffrey W. Clark, A. John Iafrate. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2010; 363 (18): 1693 DOI: 10.1056/NEJMoa1006448
  2. Bengt Hallberg, Ruth H. Palmer. Crizotinib — Latest Champion in the Cancer Wars? New England Journal of Medicine, 2010; 363 (18): 1760 DOI: 10.1056/NEJMe1010404

Cite This Page:

Massachusetts General Hospital. "New targeted lung cancer drug produces 'dramatic' symptom improvement; Early-stage trial shows promise against tumors driven by ALK gene alteration." ScienceDaily. ScienceDaily, 28 October 2010. <www.sciencedaily.com/releases/2010/10/101027170922.htm>.
Massachusetts General Hospital. (2010, October 28). New targeted lung cancer drug produces 'dramatic' symptom improvement; Early-stage trial shows promise against tumors driven by ALK gene alteration. ScienceDaily. Retrieved April 24, 2014 from www.sciencedaily.com/releases/2010/10/101027170922.htm
Massachusetts General Hospital. "New targeted lung cancer drug produces 'dramatic' symptom improvement; Early-stage trial shows promise against tumors driven by ALK gene alteration." ScienceDaily. www.sciencedaily.com/releases/2010/10/101027170922.htm (accessed April 24, 2014).

Share This



More Health & Medicine News

Thursday, April 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Big Pharma Braces for M&A Wave

Big Pharma Braces for M&A Wave

Reuters - Business Video Online (Apr. 22, 2014) — Big pharma on the move as Novartis boss, Joe Jimenez, tells Reuters about plans to transform his company via an asset exchange with GSK, and Astra Zeneca shares surge on speculation that Pfizer is looking for a takeover. Joanna Partridge reports. Video provided by Reuters
Powered by NewsLook.com
Study Says Most Crime Not Linked To Mental Illness

Study Says Most Crime Not Linked To Mental Illness

Newsy (Apr. 22, 2014) — A new study finds most crimes committed by people with mental illness are not caused by symptoms of their illness or disorder. Video provided by Newsy
Powered by NewsLook.com
Hagel Gets Preview of New High-Tech Projects

Hagel Gets Preview of New High-Tech Projects

AP (Apr. 22, 2014) — Defense Secretary Chuck Hagel is given hands-on demonstrations Tuesday of some of the newest research from DARPA _ the military's Defense Advanced Research Projects Agency program. (April 22) Video provided by AP
Powered by NewsLook.com
How Smaller Plates And Cutlery Could Make You Feel Fuller

How Smaller Plates And Cutlery Could Make You Feel Fuller

Newsy (Apr. 22, 2014) — NBC's "Today" conducted an experiment to see if changing the size of plates and utensils affects the amount individuals eat. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins